Two major phase 3 trials, CLL17 and FLAIR, are reshaping treatment for chronic lymphocytic leukemia by comparing continuous therapy with time-limited, personalized approaches.
The CLL17 trial compared three chemotherapy-free options: continuous Ibrutinib, time-limited Venetoclax plus Obinutuzumab, and time-limited Ibrutinib plus Venetoclax. All showed similar effectiveness, with about 95% progression-free survival at three years. However, patients with high-risk features like TP53 mutations may still benefit more from continuous therapy.
The FLAIR trial tested MRD-guided treatment. Patients receiving Ibrutinib plus Venetoclax had therapy duration adjusted based on response. Those who became MRD-negative continued treatment longer to deepen remission. This approach improved outcomes compared with chemotherapy but raised concerns that “time-limited” therapy may still extend for years.
Overall, these studies show that multiple effective frontline options now exist. Treatment decisions increasingly depend on genetics, patient health, and preferences, with a growing shift toward more individualized and response-based strategies.